<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131039</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00023366</org_study_id>
    <secondary_id>AVF4314S</secondary_id>
    <nct_id>NCT01131039</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer</brief_title>
  <official_title>A Phase II Trial of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether the administration of bevacizumab and&#xD;
      gemcitabine given by IV infusion can prolong survival, delay tumor growth, and/or shrink&#xD;
      tumors in patients with ovarian cancer, primary peritoneal, or fallopian tube cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI left Emory&#xD;
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The primary outcome measure is progression-free survival. Disease status and response rates will be determined by investigator assessment using RECIST or CA-125 changes (subjects with nonmeasurable disease only)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of bevacizumab in combination with gemcitabine will be assessed.</measure>
    <time_frame>2 years</time_frame>
    <description>The safety and tolerability of bevacizumab in combination with gemcitabine will be assessed using the following measures:&#xD;
- Incidence, nature, severity, and relatedness of adverse events graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE, Version 3.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Fallopian Tube Neoplasms</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine/Bevacizumab</intervention_name>
    <description>Gemcitabine: IV, days 1,8, and every 21 days&#xD;
Bevacizumab: IV, day 1 and every 21 days until disease progression</description>
    <arm_group_label>Single</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>Gemzar®</other_name>
    <other_name>Bevacizumab</other_name>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must have platinum-resistant ovarian, primary peritoneal or fallopian tube cancer.&#xD;
&#xD;
        Patients will be included in the study based on the following criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Age ≥ 19 yrs&#xD;
&#xD;
          3. Advanced, histologically documented ovarian, primary peritoneal, or fallopian tube&#xD;
             cancer&#xD;
&#xD;
          4. Measurable disease with at least one lesion that can be accurately measured in at&#xD;
             least one dimension (longest dimension recorded). Each lesion must be &gt; 20 mm when&#xD;
             measured by conventional techniques, including palpation, plain x-ray, CT and MRI, or&#xD;
             &gt; 10 mm when measured by spiral CT. OR Clinically or radiologically detectable disease&#xD;
             (ascites, peritoneal deposits, mesenteric thickening or lesions that do not fulfill&#xD;
             RECIST for measurable disease). In addition, the subject must have two consecutive&#xD;
             rising pretreatment CA-125 levels that are both &gt; 2x the institutional upper limit of&#xD;
             normal (ULN) and 40.0 IU/ml taken at least 1 week and nor more than 3 months apart.&#xD;
&#xD;
          5. Platinum-resistant or refractory cancer; subjects must not have had a biologic or&#xD;
             chemotherapeutic regimen for treatment of platinum-resistant disease prior to study&#xD;
             entry. Subjects with primary platinum-resistant cancer must have had a tumor&#xD;
             recurrence within 6 months after completing or while receiving a platinum-containing&#xD;
             regimen. These subjects must not have had any other non-platinum-containing regimen.&#xD;
             OR Subjects with secondary platinum-resistant cancer may have had any regimen with any&#xD;
             response and then have had tumor recurrence within 6 months after completing or while&#xD;
             receiving retreatment with a platinum-containing regimen. These subjects must have&#xD;
             received only two prior chemotherapeutic regimens. OR Subjects who receive a&#xD;
             chemotherapeutic regimen as consolidation after a response to a platinum-containing&#xD;
             regimen must have had tumor recurrence within 6 months after completing or while&#xD;
             receiving the consolidation regimen.&#xD;
&#xD;
          6. Life expectancy &gt; 12 weeks&#xD;
&#xD;
          7. ECOG performance status 0 or 1&#xD;
&#xD;
          8. Use of an effective means of contraception (for women of childbearing potential)&#xD;
&#xD;
          9. Clinical laboratory test results: Granulocyte count &gt; 1500/µL; Platelet count &gt;&#xD;
             75000/µL; Hemoglobin &gt; 9g/dL (hemoglobin may be supported by transfusion or&#xD;
             erythropoietin or other approved hematopoietic growth factors; darbepoetin is&#xD;
             permitted); Serum bilirubin &lt; 1.5 the ULN; alkaline phosphatase, AST, and ALT &lt; 2.5&#xD;
             ULN ( AST, ALT &lt; 5.0 ULN for subjects with liver metastasis); Serum creatinine &lt; 1.5&#xD;
             ULN; International normalized ratio (INR) &lt; 1.5 and activated partial thromboplastin&#xD;
             time (aPTT) &lt; 1.5 ULN (except for subjects receiving anti-coagulation therapy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with gemcitabine&#xD;
&#xD;
          2. Three or more prior chemotherapeutic regimens for the management of primary disease&#xD;
&#xD;
          3. Prior treatment with experimental anti-cancer agents within 4 weeks prior to Day 1&#xD;
             (the day the first study treatment infusions are administered)&#xD;
&#xD;
          4. History or clinical evidence of central nervous system or brain metastases&#xD;
&#xD;
          5. Prior treatment with Avastin or other anti-angiogenic agent&#xD;
&#xD;
          6. Uncontrolled hypercalcemia ( &gt;11.5 mg/dL)&#xD;
&#xD;
          7. History of other malignancies within 5 years of Day 1, except for adequately treated&#xD;
             carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of breast, basal or&#xD;
             squamous cell skin cancer&#xD;
&#xD;
          8. History of serious systemic disease, unstable angina, myocardial infarction, stroke,&#xD;
             transient ischemic attack,, symptoms of CHF, or unstable symptomatic arrhythmia&#xD;
             requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial&#xD;
             fibrillation, paroxysmal supraventricular tachycardia, are eligible) within 6 months&#xD;
             prior to Day 1 of treatment&#xD;
&#xD;
          9. Known HIV infection&#xD;
&#xD;
         10. Pregnancy or lactation&#xD;
&#xD;
         11. Major surgery, open biopsy, or significant traumatic injury within 4 weeks prior to&#xD;
             Day 1 of treatment, or anticipation of need for major surgical procedure during the&#xD;
             course of the study&#xD;
&#xD;
         12. Inability to comply with study and follow-up procedures&#xD;
&#xD;
         13. Any other diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the subject at high risk from treatment&#xD;
             complications&#xD;
&#xD;
         14. Life expectancy of less than 12 weeks&#xD;
&#xD;
         15. Current, recent (within 4 weeks of the first infusion of this study), or planned&#xD;
             participation in an experimental drug study other than a Genentech-sponsored&#xD;
             bevacizumab cancer study&#xD;
&#xD;
         16. Inadequately controlled hypertension (defined as systolic blood pressure &gt;150 and/or&#xD;
             diastolic blood pressure &gt; 100 mmHg on antihypertensive medications)&#xD;
&#xD;
         17. Any prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
         18. New York Heart Association (NYHA) Grade II or greater congestive heart failure (see&#xD;
             Appendix E)&#xD;
&#xD;
         19. Known CNS disease&#xD;
&#xD;
         20. Significant vascular disease (e.g., aortic aneurysm, aortic dissection)&#xD;
&#xD;
         21. Symptomatic peripheral vascular disease&#xD;
&#xD;
         22. Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
         23. Any patient that the clinician considers at risk for possible GI perforation. This&#xD;
             includes patients with clinical symptoms or signs of GI obstruction or who require&#xD;
             parenteral nutrition, parenteral hydration, or tube feeding, and patients with&#xD;
             evidence of free air not explained by paracentesis or recent surgical procedure.&#xD;
&#xD;
         24. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to study enrollment&#xD;
&#xD;
         25. Core biopsy or other minor surgical procedure, excluding placement of a vascular&#xD;
             access device, within 7 days prior to study enrollment&#xD;
&#xD;
         26. Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
         27. Proteinuria at screening as demonstrated by either Urine protein:creatinine (UPC)&#xD;
             ratio ≥ 1.0 at screening OR Urine dipstick for proteinuria ≥ 2+ (patients discovered&#xD;
             to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour&#xD;
             urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).&#xD;
&#xD;
         28. Known hypersensitivity to any component of bevacizumab&#xD;
&#xD;
         29. Pregnant (positive pregnancy test) or lactating. Use of effective means of&#xD;
             contraception (men and women) in subjects of child-bearing potential&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharmila Makhija, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>December 19, 2013</last_update_submitted>
  <last_update_submitted_qc>December 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

